|
Market Closed -
Nasdaq
16:00:00 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 15.07 USD | +3.65% |
|
-2.65% | -34.48% |
| 09-03 | Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose | RE |
| 09-03 | Top Midday Decliners | MT |
| Market Cap | 1.43B 1.27B 1.18B 1.07B 2.02B 136B 2.05B 14.17B 5.56B 70.84B 5.36B 5.25B 227B | P/E 2026 * |
-3.85x | P/E 2027 * | -24.7x |
|---|---|---|---|---|---|
| Enterprise Value | 1B 894M 828M 753M 1.41B 95.12B 1.44B 9.93B 3.9B 49.68B 3.76B 3.68B 159B | EV / Sales 2026 * |
1.32x | EV / Sales 2027 * | 0.91x |
| Free-Float |
96.27% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| RARE | Delayed | |
CBOE
| RARE | Real-time | |
|
Tradegate
| UP0 | Real-time | |
|
Berne S.E.
| UP0 | End-of-day quote | |
|
Mexican S.E.
| RARE * | End-of-day quote | |
|
London S.E.
| 0LIF | Delayed | |
|
Boerse Muenchen
| UP0 | Real-time | |
|
Deutsche Boerse AG
| UP0 | Delayed | |
|
Börse Stuttgart
| UP0 | Delayed |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | +3.65% | ||
| 1 week | -2.65% | ||
| Current month | +0.27% | ||
| 1 month | +3.86% | ||
| 3 months | -48.53% | ||
| 6 months | -39.26% | ||
| Current year | -34.48% |
| 1 week | 14.44 |  | 15.39 |
| 1 month | 14.08 | | 16.12 |
| Current year | 12.73 | | 36.57 |
| 1 year | 12.73 | | 39.89 |
| 3 years | 12.73 | | 60.37 |
| 5 years | 12.73 | | 89.56 |
| 10 years | 12.73 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 2010-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 2023-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 2023-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 2010-04-21 |
Matthew Fust
BRD | Director/Board Member | 62 | 2013-12-31 |
Michael Narachi
BRD | Director/Board Member | 66 | 2015-02-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/15/26 | Sell | Controller/Auditor | -1,283 | 0.0013% | ||
| 9/3/26 | Sell | Controller/Auditor | -161 | 0.0002% | ||
| 8/3/26 | Sell | General Counsel | -1,900 | 0.0019% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.65% | -2.65% | -53.82% | -52.51% | 1.43B | |
| -1.33% | +5.18% | +54.50% | +104.26% | 1,120B | |
| -0.69% | -2.93% | +31.35% | +66.17% | 616B | |
| -0.96% | +2.25% | +23.13% | +89.36% | 504B | |
| +0.24% | +6.23% | +33.98% | +52.38% | 367B | |
| -1.59% | -1.35% | +69.39% | +40.83% | 360B | |
| -0.40% | +4.28% | +19.17% | +42.51% | 288B | |
| -0.37% | +3.35% | -1.26% | +16.85% | 258B | |
| -1.75% | +2.43% | +42.21% | +49.85% | 234B | |
| -2.00% | +1.26% | +24.64% | +92.13% | 194B | |
| Average | -0.29% | +2.37% | +24.33% | +50.18% | 394.23B | |
| Weighted average by Cap. | -0.73% | +3.51% | +37.86% | +71.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 760M 677M 628M 571M 1.07B 72.1B 1.09B 7.53B 2.96B 37.65B 2.85B 2.79B 120B | 989M 882M 818M 743M 1.4B 93.9B 1.42B 9.81B 3.85B 49.04B 3.71B 3.63B 157B |
| Net income | -413M -369M -342M -311M -583M -39.24B -592M -4.1B -1.61B -20.49B -1.55B -1.52B -65.53B | -79.05M -70.5M -65.35M -59.41M -112M -7.5B -113M -784M -308M -3.92B -297M -290M -12.53B |
| Net Debt | -427M -381M -353M -321M -602M -40.52B -612M -4.23B -1.66B -21.16B -1.6B -1.57B -67.67B | -531M -474M -439M -399M -750M -50.44B -762M -5.27B -2.07B -26.34B -1.99B -1.95B -84.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-19 | US$15.07 | +3.65% | 2,983,990 |
| 26-10-16 | US$14.54 | -4.15% | 2,926,825 |
| 26-10-15 | US$15.17 | +1.81% | 3,332,835 |
| 26-10-14 | US$14.90 | -0.13% | 2,955,623 |
| 26-10-13 | US$14.92 | -2.48% | 5,306,280 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
Select your edition
All financial news and data tailored to specific country editions
